Growth N. V. Biotech Buys 50,000 Shares of Radius Health, Inc. (RDUS) Stock
Radius Health, Inc. (NASDAQ:RDUS) major shareholder Growth N. V. Biotech acquired 50,000 shares of Radius Health stock in a transaction that occurred on Tuesday, September 5th. The shares were bought at an average cost of $36.75 per share, with a total value of $1,837,500.00. Following the transaction, the insider now owns 5,298,799 shares in the company, valued at $194,730,863.25. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Large shareholders that own more than 10% of a company’s stock are required to disclose their transactions with the SEC.
Shares of Radius Health, Inc. (NASDAQ RDUS) opened at 36.60 on Friday. Radius Health, Inc. has a one year low of $31.58 and a one year high of $59.22. The company’s market cap is $1.59 billion. The company has a 50 day moving average price of $38.51 and a 200 day moving average price of $39.43.
Radius Health (NASDAQ:RDUS) last released its earnings results on Thursday, August 3rd. The biopharmaceutical company reported ($1.58) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.35) by $0.23. The company had revenue of $0.98 million during the quarter, compared to analysts’ expectations of $1.96 million. During the same quarter last year, the firm posted ($1.01) earnings per share. Equities analysts predict that Radius Health, Inc. will post ($5.58) EPS for the current year.
Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. DUPONT CAPITAL MANAGEMENT Corp acquired a new position in shares of Radius Health in the 1st quarter valued at $304,000. OppenheimerFunds Inc. increased its position in shares of Radius Health by 0.3% in the 1st quarter. OppenheimerFunds Inc. now owns 301,631 shares of the biopharmaceutical company’s stock valued at $11,658,000 after acquiring an additional 831 shares during the period. American International Group Inc. increased its position in shares of Radius Health by 7.1% in the 1st quarter. American International Group Inc. now owns 19,430 shares of the biopharmaceutical company’s stock valued at $751,000 after acquiring an additional 1,284 shares during the period. Trexquant Investment LP acquired a new position in shares of Radius Health in the 1st quarter valued at $241,000. Finally, BlackRock Inc. increased its position in shares of Radius Health by 98,245.6% in the 1st quarter. BlackRock Inc. now owns 2,630,745 shares of the biopharmaceutical company’s stock valued at $101,679,000 after acquiring an additional 2,628,070 shares during the period.
A number of research analysts recently weighed in on RDUS shares. Jefferies Group LLC set a $34.00 price objective on Radius Health and gave the company a “hold” rating in a research report on Monday, June 5th. ValuEngine raised Radius Health from a “sell” rating to a “hold” rating in a report on Thursday, June 22nd. BidaskClub raised Radius Health from a “hold” rating to a “buy” rating in a report on Tuesday, June 27th. Zacks Investment Research raised Radius Health from a “sell” rating to a “hold” rating in a report on Tuesday, August 8th. Finally, Cantor Fitzgerald set a $65.00 target price on Radius Health and gave the stock a “buy” rating in a report on Monday, May 22nd. Two equities research analysts have rated the stock with a sell rating, four have given a hold rating and four have assigned a buy rating to the company. The stock has a consensus rating of “Hold” and a consensus target price of $53.60.
Radius Health Company Profile
Radius Health, Inc is a biopharmaceutical company. The Company is focused on the developing therapeutics in the areas of osteoporosis, oncology and endocrine diseases. The Company’s lead investigational product candidate, TYMLOS (abaloparatide-SC) injection is developed for the treatment of postmenopausal women with osteoporosis at high risk for fracture.
Receive News & Stock Ratings for Radius Health Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Radius Health Inc. and related stocks with our FREE daily email newsletter.